Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(22%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
6%
Ph early_phase_1
9
50%
Ph phase_1
3
17%
Ph not_applicable
3
17%

Phase Distribution

12

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
9(56.3%)
Phase 1Safety & dosage
3(18.8%)
Phase 2Efficacy & side effects
1(6.3%)
N/ANon-phased studies
3(18.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

18

all time

Status Distribution
Active(4)
Completed(1)
Terminated(1)
Other(12)

Detailed Status

unknown12
Recruiting4
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
4
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 19 (56.3%)
Phase 13 (18.8%)
Phase 21 (6.3%)
N/A3 (18.8%)

Trials by Status

unknown1267%
recruiting422%
withdrawn16%
completed16%

Recent Activity

4 active trials
Showing 5 of 18
recruitingphase_1

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT

NCT07062523
recruitingnot_applicable

68Ga-FAPI PET/CT in Malignant Tumors

NCT05034146
recruitingphase_1

Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT

NCT05121779
withdrawnphase_2

68-Ga-FAPI PET Imaging in Malignancy

NCT04023240
recruitingearly_phase_1

68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients

NCT05543954
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT07062523Phase 1

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT

Recruiting
NCT05034146Not Applicable

68Ga-FAPI PET/CT in Malignant Tumors

Recruiting
NCT05121779Phase 1

Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT

Recruiting
NCT04023240Phase 2

68-Ga-FAPI PET Imaging in Malignancy

Withdrawn
NCT05543954Early Phase 1

68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients

Recruiting
NCT05856409

Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence

Unknown
NCT05952531Early Phase 1

Characterizing Myositis With 68Ga-FAPI PET/CT

Unknown
NCT05275699Phase 1

Analyse of Diagnosis Value of Keloid on 68Ga- FAPI-04 PET-CT

Completed
NCT05803629Not Applicable

Characterizing Histiocytosis With 68Ga-FAPI PET/CT

Unknown
NCT05691894Early Phase 1

Tracer Targeting FAP PET Imaging in Patients

Unknown
NCT05686876Early Phase 1

FAPI-PET/CT in Psoriatic Arthritis

Unknown
NCT04982458

Visualized Monitoring of Fibrosis Formation in Heart Failure With 68GA-FAPI PET

Unknown
NCT05499936Not Applicable

68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Unknown
NCT05036759Early Phase 1

68Ga-FAPI PET/MR for Atherosclerosis

Unknown
NCT04507932Early Phase 1

Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT

Unknown
NCT04125511Early Phase 1

Characterizing IgG4-RD With 68Ga-FAPI PET/CT

Unknown
NCT04514614Early Phase 1

Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT

Unknown
NCT04596462Early Phase 1

Characterizing SAPHO With 68Ga-FAPI PET/CT

Unknown

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18